Molecular pathways: Interleukin-35 in autoimmunity and cancer

34Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

Immunosuppressive functions conferred by regulatory cytokines are important for maintaining homeostasis in immune responses. IL35 has recently emerged as a novel regulator of immune responses. Once thought to be specifically expressed by T regulatory cells, induction of IL35 expression has now been detected in multiple cell types in a variety of diseases, prompting research into regulation of its expression, signaling specificity, target cell populations, and functional outputs. Recent studies have revealed that by directing de novo generation of regulatory T and B cells and inhibiting T effector responses, IL35 plays an important role in the development of autoimmune diseases and cancer. IL35 is overexpressed in a variety of cancers and may exert its function both on antitumor immune responses as well as directly on tumor cells. As such, IL35 is rapidly emerging as a promising biomarker and an attractive cancer therapy target.

Cite

CITATION STYLE

APA

Pylayeva-Gupta, Y. (2016). Molecular pathways: Interleukin-35 in autoimmunity and cancer. Clinical Cancer Research, 22(20), 4973–4978. https://doi.org/10.1158/1078-0432.CCR-16-0743

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free